Roche Expects Sales, Core Earnings Growth
Provided by
Dow Jones
By Adria Calatayud
Roche Holding expects growth in sales and core earnings to pick up this year after waning demand for Covid-19 products and currency headwinds weighed on its top and bottom lines last year.
The Swiss pharmaceutical giant said Thursday that it expects sales growth in the mid single digit percentage range at constant exchange rates in 2024, with core earnings per share performing in line with sales when excluding the impact from tax disputes in 2023.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
February 01, 2024 01:31 ET (06:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?